Deutsche Bank AG Purchases 6,113 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Deutsche Bank AG increased its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 52.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,867 shares of the biotechnology company’s stock after acquiring an additional 6,113 shares during the period. Deutsche Bank AG owned about 0.06% of AnaptysBio worth $237,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Bridgefront Capital LLC bought a new stake in AnaptysBio during the 4th quarter worth $252,000. Boxer Capital Management LLC bought a new stake in AnaptysBio during the 4th quarter worth $17,212,000. Northern Trust Corp grew its position in AnaptysBio by 10.0% during the 4th quarter. Northern Trust Corp now owns 219,986 shares of the biotechnology company’s stock worth $2,913,000 after acquiring an additional 20,073 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in AnaptysBio during the 4th quarter worth $593,000. Finally, Virtus ETF Advisers LLC grew its position in AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 936 shares during the last quarter.

Wall Street Analyst Weigh In

ANAB has been the topic of a number of research reports. Wolfe Research initiated coverage on AnaptysBio in a research report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 price objective on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. Wells Fargo & Company lifted their target price on AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $36.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Finally, Guggenheim reaffirmed a “buy” rating and set a $90.00 target price (up from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $40.38.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $22.45 on Monday. The company has a market capitalization of $659.58 million, a price-to-earnings ratio of -3.69 and a beta of -0.20. The business’s 50-day moving average is $19.73 and its 200-day moving average is $18.23. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. Analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has approved a stock repurchase program on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to purchase up to 13.1% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.